£4.6m · Seed · Healthtech · London, UK
London-based Stride has raised £4.6m in seed funding from Arāya Ventures, Better Ventures, Morgan Stanley Inclusive & Sustainable Ventures and Innovate UK, alongside angel investors. The company's first external round will fund a broader testing range, a multi-source biological-age product and the US launch of its StrideOne membership.
Founded by former Olympic sprinter and DNAfit co-founder Andrew Steele, Stride combines DNA, blood and gut-microbiome testing with practitioner consultations and personalised action plans. Its model is designed around repeated measurement: members establish a baseline, make changes to diet, exercise, sleep or supplements, and retest to see how selected markers have moved.
Turning a test kit into an ongoing service
Many consumer-testing businesses are built around a single purchase. Stride is trying to create a longer customer relationship by joining several tests in one account, adding quarterly practitioner support and repeating blood and gut tests every six months. That cadence can produce recurring revenue while giving customers a reason to return beyond receiving their first report.
The company says more than 16,000 people have used its products and that 85% of StrideOne members were retained through the first 13 months. Those are company-reported figures, but they point to the commercial question the seed round can now test at greater scale: whether guidance and retesting make the service durable enough to support the cost of laboratories, practitioners and customer acquisition.
US expansion tests more than demand
Stride says the funding will also support a US launch of StrideOne and research into a biological-age test that combines several data sources. International expansion could widen the addressable market, but it also introduces different laboratory, regulatory and clinical-service requirements. The company will need to preserve a coherent customer experience while adapting how samples are collected, results are interpreted and health claims are communicated.
The product's value therefore depends on more than collecting additional biomarkers. Stride has to show that combining results produces priorities customers can understand and act on, and that retesting supplies meaningful feedback rather than a larger dashboard. If that loop is useful, the membership can shift preventive testing from an occasional purchase towards an ongoing service; if it is not, the expanded product range risks adding complexity without improving retention.
Sources checked:
Stride announcement · Tech.eu report · Stride product site · Stride science · Tech.eu Funding Explorer
